We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the first subjects have been dosed in Phase I study in healthy volunteers evaluating the Company’s lead drug candidate…
Infex Awarded Biomedical Catalyst Grant For COV-X Project
Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18 month, £1m COV-X project, titled: “Optimisation of a novel…
COVID-19 Pandemic Triggers Upsurge in MBL Infections
New research has discovered that the ongoing COVID-19 pandemic has triggered a significant upsurge in metallo-β-lactamase (MBL) infections.
Latest News
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the…
Infex Awarded Biomedical Catalyst Grant For COV-X Project
Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a…
CARB-X Receives Additional $370m from U.S. Government and Wellcome
Enables continued investment in innovative projects to tackle the growing global threat…
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022
Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism
Infex Therapeutics, one of the UK’s leading infectious disease biotech companies, has…
Infex scientists achieve breakthrough to overcome critical priority drug resistant infections
One of the UK’s leading infectious disease biotech companies has announced a breakthrough…
Infex agrees partnership with Colibri Scientific to provide services for RESP-X program
Infex Therapeutics has today announced a deal with Colibri Scientific, to provide…
Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
One of the UK’s leading infectious disease biotech companies has announced a breakthrough…
Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics
“The announcement today that the government is increasing public R&D investment to record…